Pain Neuroscience Education in Patients With Fibromyalgia
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04050839 |
Recruitment Status :
Completed
First Posted : August 8, 2019
Last Update Posted : April 4, 2022
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
Pain, Chronic Fibromyalgia | Other: Pain neuroscience education Drug: Medical treatment | Not Applicable |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 40 participants |
Allocation: | Randomized |
Intervention Model: | Factorial Assignment |
Masking: | Single (Outcomes Assessor) |
Primary Purpose: | Treatment |
Official Title: | The Effectiveness of Pain Neuroscience Education in Patients With Fibromyalgia |
Actual Study Start Date : | September 15, 2019 |
Actual Primary Completion Date : | June 15, 2021 |
Actual Study Completion Date : | July 15, 2021 |

Arm | Intervention/treatment |
---|---|
Experimental: Neuroscience pain education group
Pain neuroscience education in addition medical treatment
|
Other: Pain neuroscience education
A total of 4 NPE (Neuroscience paine education) sessions were held, once each week in addition medical treatment similar to control group. The NPE sessions were conducted by an experienced physiotherapist certified in NPE in face-to-face, group sessions lasting 40-45 minutes. In NPE, the patient is taught about the physiology of pain, central sensitization, representation of the different body regions in the brain, pain-related changes in body perception, and the psychosocial dimensions of pain. Drug: Medical treatment The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians. |
Active Comparator: Control group
Medical treatment only
|
Drug: Medical treatment
The patients in control group continued taking their regular gabapentin and pregabalin-derivative drug therapy at the same dosage and duration specified by their physicians. |
- Fibromyalgia Impact Questionnaire (FIQ) [ Time Frame: Change from Baseline FIQ at 4th weeks ]The FIQ is an assessment and evaluation instrument developed to measure fibromyalgia (FM) patient status, progress and outcomes
- Pressure pain thresholds (PPT) [ Time Frame: Change from Baseline PPT at 4th weeks ]Pressure pain thresholds in following five points, 7th cervical vertebra, 3th lumbal vertebra, 5th lumbal vertebra, the belly of calf muscles, and 2nd distal interfalangeal joint were measured using a analog pressure algometer(Baseline, USA).
- Tinel's Sign [ Time Frame: Change from Baseline PPT at 4th weeks ]The Tinel sign is the result of a simple, noninvasive test that checks for nerve problems. The test is positive when a tingling or prickling sensation is felt in the distribution of the Tibial nerve.
- Tampa Scale of Kinesiophobia [ Time Frame: Change from Baseline PPT at 4th weeks ]The Tampa Scale for Kinesiophobia (TSK) was used for the assessment of kinesiophobia. The TSK is a 17-item questionnaire developed to measure the fear of movement/re-injury.

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- have fibromyalgia as defined by the criteria of the 1990 ACR
- have Turkish as their native language
- between 18 and 65 years of age
Exclusion Criteria:
- Having cognitive impairment
- Receiving psychotherapy
- Illiterate people
- Patients with significant hearing loss

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04050839
Turkey | |
KutahyaMSU | |
Kütahya, Kutahya Health Sciences University, Turkey, 43000 |
Responsible Party: | Ismail Saracoglu, Principal Investigator, Kutahya Health Sciences University |
ClinicalTrials.gov Identifier: | NCT04050839 |
Other Study ID Numbers: |
KutahyaMSUfibro |
First Posted: | August 8, 2019 Key Record Dates |
Last Update Posted: | April 4, 2022 |
Last Verified: | March 2022 |
Individual Participant Data (IPD) Sharing Statement: | |
Plan to Share IPD: | No |
Studies a U.S. FDA-regulated Drug Product: | No |
Studies a U.S. FDA-regulated Device Product: | No |
pain neuroscience education patient education |
Fibromyalgia Myofascial Pain Syndromes Chronic Pain Muscular Diseases Musculoskeletal Diseases |
Rheumatic Diseases Neuromuscular Diseases Nervous System Diseases Pain Neurologic Manifestations |